AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
CERo Therapeutics Soars 89.72% on FDA Orphan Designation
Generated by AI AgentAinvest Pre-Market Radar
Tuesday, Jun 17, 2025 7:24 am ET1min read
On June 17, 2025,
surged 89.72% in pre-market trading, marking a significant rise in its stock price.The Food and Drug Administration has granted orphan designation to a drug under development by CeroTherapeutics aimed at treating acute myeloid leukemia. This designation is a significant step for the company as it seeks to advance its treatment options for this challenging blood cancer.
Wall Street analysts have set an average price target of $60.00 for CERo Therapeutics, with a high estimate of $60.00 and a low estimate of $60.00. This target implies an upside of 773.62% from the current price. The consensus recommendation from brokerage firms indicates an "Outperform" status for the company, with an average rating of 2.5 on a scale where 1 signifies Strong Buy and 5 denotes Sell.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Standard BioTools Inc. plunged 11.01% due to delayed clinical trial submissions and supply chain disruptions.
Dec.24 2025
United States Antimony Corporation shares surge 7.87% on operational advancements and sector tailwinds
Dec.24 2025
SEALSQ Shares Plunged 5.88% in Pre-Market Trading on Dec. 24 2025 as Heightened Investor Caution Ahead of Year-End Holiday Weighs
Dec.24 2025
ASST plunges 6.98% in pre-market as Bitcoin strategy volatility and market challenges weigh
Dec.24 2025
Poet Technologies (NASDAQ: POET) Falls 6.04% as Investor Caution Ahead of AI Infrastructure Execution Phase
Dec.24 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet